# US 2004/0018153 A1 · HFA suspension formulations containing an anticholinergic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018153 A1
- Document ID: US20040018153A1
- Status: Published application
- Kind: A1
- Application number: 10/392,559
- Filed: 2003-03-20
- Published: 2004-01-29
- Earliest claimed: 2002-03-28
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Christel Schmelzer
- Web page: https://patentgrep.com/patent/US20040018153A1

## CPC

- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61P 11/06: Antiasthmatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.

## Claims

### Claim 1

1) A suspension of crystalline tiotropium bromide monohydrate in propellant gases HFA 227 and/or HFA 134a, optionally in admixture with one or more other propellant gases chosen from propane, butane, pentane, dimethylether, CHClF2, CH2F2, CF3CH3, isobutane, isopentane and neopentane.

### Claim 2 (depends on 1)

2) The suspension according to claim 1, wherein the amount of tiotropium bromide is between 0.001 and 0.8%.

### Claim 3 (depends on 2)

3) The suspension according to claim 2, further containing other ingredients chosen from surfactants, adjuvants, antioxidants and flavourings or combinations thereof.

### Claim 4 (depends on 3)

4) The suspension according to claim 3, wherein the surfactants are one or more compounds chosen from Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropylmyristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol or combinations thereof.

### Claim 5 (depends on 3)

5) The suspension according to claim 3, wherein the adjuvants are one or more compounds chosen from alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid or combinations thereof.

### Claim 6 (depends on 3)

6) The suspension according to claim 3, wherein the antioxidants are one or more compounds chosen from ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate or combinations thereof.

### Claim 7 (depends on 1, 2)

7) The suspension according to claim 1 or 2, wherein they contain no other ingredients apart from the active substance and the propellant gas or gases.

### Claim 8 (depends on 1)

8) A method of treating a disease, said disease being chosen from those in which an anticholinergic confers a therapeutic benefit, said method comprising administering by inhalation or nasal route to a patient in need thereof a therapeutically effect amount of a suspension according to claim 1.

### Claim 9 (depends on 1)

9) A method of treating a respiratory complaints disease, said method comprising administering to a patient in need thereof a therapeutically effect amount of a suspension according to claim 1.

### Claim 10 (depends on 9)

10) The method according to claim 9, wherein the diseases are chosen from asthma and COPD.
